Cuprina Holdings (Cayman) Limited Announces Pricing of $4.97 million Public Offering
Cuprina plans to raise up to about $5.72 million in gross proceeds through a newly priced public share offering.
Rhea-AI Summary
Cuprina Holdings (CUPR) priced a firm commitment public offering of 4,322,489 Class A ordinary shares at $1.15 per share on September 16, 2026.
The offering is expected to generate approximately $4.97 million in gross proceeds before underwriting discounts and expenses. The company granted the underwriter a 45-day option to purchase up to 648,373 additional shares at the same price, which would increase gross proceeds to about $5.72 million if fully exercised. The offering is expected to close on or about September 17, 2026, subject to customary closing conditions, and is made under an effective SEC Form F-1 registration statement.
Positive
- Gross proceeds of approximately $4.97 million from 4,322,489 shares at $1.15 each, before discounts and expenses
- Over-allotment option for 648,373 shares could lift gross proceeds to about $5.72 million if fully exercised
- Offering backed by effective SEC Form F-1 (File No. 333-297299) declared effective on September 15, 2026
Negative
- Share issuance of up to 4,970,862 shares including over-allotment, implying dilution for existing shareholders
- Net proceeds will be below $4.97–$5.72 million after underwriting discounts, commissions and offering expenses
News Explained
The priced offering is not yet closed: if completed, issuing its 4,322,489 Class A shares would increase total shares and reduce existing holders’ percentage ownership absent offsetting changes.
Details
Market reaction after firm-commitment public offering: CUPR -45.73%
Following this news, CUPR has declined 45.73%, reflecting a significant negative market reaction. Argus tracked a trough of -22.3% from its starting point during tracking. Our momentum scanner has triggered 26 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $1.59. Trading volume is exceptionally heavy at 373.0x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Shares offered
- 4,322,489 shares
- Firm-commitment public offering
- Offering price
- $1.15 per share
- Public offering
- Gross proceeds
- $4.97 million
- Before underwriting discounts and offering expenses
- Over-allotment option
- 648,373 shares
- 45-day underwriter option
- Over-allotment percentage
- 15%
- Of Class A Ordinary Shares sold
- Gross proceeds with over-allotment
- $5.72 million
- Before underwriting discounts, commissions and offering expenses
- Expected offering close
- September 17, 2026
- Subject to customary closing conditions
- Registration statement effectiveness
- September 15, 2026
- Form F-1 declared effective by the SEC
Key Terms
firm commitment public offering financial
over-allotment financial
form f-1 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SINGAPORE, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced the pricing of its firm commitment public offering of an aggregate 4,322,489 shares of its Class A Ordinary Shares (“the Offering”), all of which are being offered by CUPR at a public offering price of
The Company has granted the underwriter a 45-day option to purchase up to an additional 648,373 shares of its Class A Ordinary Shares at the Offering Price, representing
The Offering is expected to close on or about September 17, 2026, subject to the satisfaction of customary closing conditions.
R. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole book-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney Westwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman Islands legal counsels to the Company, respectively, and Ellenoff Grossman & Schole LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering.
The Offering is being conducted pursuant to the Company’s Registration Statement on Form F-1 (File No: 333-297299) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on September 15, 2026. The Offering is being made only by means of a prospectus. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. Copies of the final prospectus related to the Offering may be obtained, when available, from R. F. Lafferty & Co., Inc., 40 Wall Street, Suite 3602, New York, NY 10005; (212) 293-9090, or by email at offerings@rflafferty.com. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC’s website at www.sec.gov.
This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the infertility, medical waste recycling, and health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https:// www.cuprina.com.
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected completion, timing and gross proceeds of the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the key terms of Cuprina’s new public offering?
The offering covers 4,322,489 Class A ordinary shares at a public offering price of $1.15 per share, for gross proceeds of about $4.97 million before underwriting discounts and offering expenses. There is also a 45-day over-allotment option for the underwriter to buy up to 648,373 additional shares at the same price, which would raise total gross proceeds to approximately $5.72 million if fully exercised.
When is the offering expected to close?
The offering is expected to close on or about September 17, 2026, subject to the satisfaction of customary closing conditions.
Under which SEC filing is this offering being conducted?
The offering is being conducted pursuant to Cuprina’s Registration Statement on Form F-1 (File No. 333-297299), which was declared effective by the U.S. Securities and Exchange Commission on September 15, 2026.
Who is acting as book-running manager and legal counsel for the offering?
R. F. Lafferty & Co., Inc. is the sole book-running manager. Loeb & Loeb LLP, Lee & Lee, and Harney Westwood & Riegels Singapore LLP serve as U.S., Singapore and Cayman Islands legal counsels to Cuprina, respectively, and Ellenoff Grossman & Schole LLP is U.S. legal counsel to R. F. Lafferty.
How can investors obtain the final prospectus for this offering?
Copies of the final prospectus, when available, may be obtained from R. F. Lafferty & Co., Inc., 40 Wall Street, Suite 3602, New York, NY 10005, by calling (212) 293-9090, or by email at offerings@rflafferty.com. The final prospectus, when available, can also be accessed via the SEC website at www.sec.gov.